Roberto Bellini (@rbellini) header
Roberto Bellini (@rbellini) profile picture

Managing Partner BSQUARED Capital and Former CEO of @BellusHealth

Montreal, Canada
Joined February 2009
I'm gutted. This is a significant blow for chronic cough patients who still have no US approved therapy and for the field broadly. Detailed results will help us better understand what happened and learnings/implications for current/future drugs in development.
$GSK shelving development of camlipixant on mixed/disappointing results from two Ph3 studies. This is the drug GSK acquired for $2B rom Bellus Health in 2023. gsk.com/en-gb/media/press-re…
7
7
1
49
19,458
Roberto Bellini retweeted
🎙️ On this week's episode of Tank Talks, I sit down with @rbellini, Co-Founder of BSQUARED Capital and former CEO of @BellusHealth for a powerful conversation about family, legacy, and resilience in biotech. We originally recorded this episode just two weeks before the sudden passing of his father, Dr. Francesco Bellini — known as “Mr. Biotech Canada.” After his passing, Roberto and I decided to re-record the episode as a heartfelt tribute to his father’s incredible impact on the Canadian biotech industry. This is the first time Roberto speaks publicly since his father's passing and opens up about: - Growing up with a front-row seat to the rise of Biochem Pharma and its $6B exit. - The highs and lows of leading Bellus Health, from near collapse to a $2B acquisition by GSK. - How BSQUARED Capital is helping shape the next generation of biotech innovators in Canada. - Lessons on leadership, perseverance, and the true meaning of legacy. This episode goes beyond business success — it’s about honouring a visionary, learning through adversity, and building something that lasts.
1
1
9
337
Excited to be joining the Board and part of this story!
This quoted post is unavailable.
1
1
24
4,523
Being a Biotech CEO is a Tough Job Example #273 The Everything is Awesome CEO exists and fails to connect with investors for all the reasons that Josh Schimmer(@biotech1) lists in his Weekend Musing (below) but even the best CEOs struggle with communicating business challenges.🧵
Weekend Musing: The CEO Who Cried Awesome "They are the CEOs who always say everything is going perfectly according to plan, even when it's clearly not" An excerpt from Josh Schimmer at Cantor
2
8
2,635
Why do EIACEOs exist? Survival bias. Investors allocate capital to these CEOs and their projects. Many investors like the positivity particularly once their invested. I’ve been berated by an investor for talking about risks that they thought weren’t pertinent.
1
286
IMPORTANT: If we want to encourage more transparency and openness from our biotech CEOs, we need to reward them for it.
1
2
331
Roberto Bellini retweeted
RBC Global Healthcare Conference: Catching up with @rbellini one year after he sold BELLUS Health to GSK for $2 billion. Full video: biotechtv.com/post/roberto-b…
4
15
5,637
Providing management teams more flexibility wrt cash runway would be hugely valuable. Let me tell you why I'm in favor of changing the convention of biotechs always needing 12 months of cash (+ some caveats). My thoughts after reading @PeterKolchinsky and Tess' thoughtful piece.
1
4
2
30
19,764
I could also imagine it being dificult from an HR perspective. Peter and Tess note this for internal employee morale but it would have the biggest negative impact on recruitment. Attracting top talent with a weak balance sheet is hard.
1
692
Overall, letting management teams figure out what the right buffer amount is in their plan without needing to check the '+12 month runway' box would be great. In some cases, running down the cash <12 months make sense. I would love to see more companies normalize this option. //
3
628